JAK–STAT pathway targeting for the treatment of inflammatory bowel disease

A Salas, C Hernandez-Rocha, M Duijvestein… - Nature reviews …, 2020 - nature.com
Cytokines are involved in intestinal homeostasis and pathological processes associated
with inflammatory bowel disease (IBD). The biological effects of cytokines, including several …

A comprehensive review and update on ulcerative colitis

M Gajendran, P Loganathan, G Jimenez, AP Catinella… - Disease-a-month, 2019 - Elsevier
Ulcerative colitis (UC) is a chronic idiopathic inflammatory bowel disorder of the colon that
causes continuous mucosal inflammation extending from the rectum to the more proximal …

Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery

J Zhou, M Li, Q Chen, X Li, L Chen, Z Dong… - Nature …, 2022 - nature.com
Reactive oxygen species (ROS) play vital roles in intestinal inflammation. Therefore,
eliminating ROS in the inflammatory site by antioxidant enzymes such as catalase and …

STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD …

D Turner, A Ricciuto, A Lewis, F D'amico, J Dhaliwal… - Gastroenterology, 2021 - Elsevier
Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …

ACG clinical guideline: ulcerative colitis in adults

DT Rubin, AN Ananthakrishnan… - Official journal of the …, 2019 - journals.lww.com
Ulcerative colitis (UC) is an idiopathic inflammatory disorder. These guidelines indicate the
preferred approach to the management of adults with UC and represent the official practice …

[PDF][PDF] Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management

M Harbord, R Eliakim, D Bettenworth… - Journal of Crohn's …, 2017 - academic.oup.com
11.1. General The treatment strategy for ulcerative colitis [UC] is mainly based on the
severity, distribution [proctitis, left-sided, extensive] 1 and pattern of disease. The latter …

Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus

A Rezaie, M Buresi, A Lembo, H Lin… - Official journal of the …, 2017 - journals.lww.com
Objectives: Breath tests (BTs) are important for the diagnosis of carbohydrate maldigestion
syndromes and small intestinal bacterial overgrowth (SIBO). However, standardization is …

[HTML][HTML] Disease monitoring in inflammatory bowel disease: evolving principles and possibilities

N Plevris, CW Lees - Gastroenterology, 2022 - Elsevier
Inflammatory bowel disease is a progressive and debilitating condition. Early and effective
treatment utilizing a treat to target approach is key in improving patient outcomes. Therefore …

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of …

WJ Sandborn, N Lawendy, S Danese… - Alimentary …, 2022 - Wiley Online Library
Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of
ulcerative colitis. We present final data from OCTAVE Open, an open‐label, long‐term …

The Toronto consensus for the treatment of Helicobacter pylori infection in adults

CA Fallone, N Chiba, SV van Zanten, L Fischbach… - Gastroenterology, 2016 - Elsevier
Background & Aims Helicobacter pylori infection is increasingly difficult to treat. The purpose
of these consensus statements is to provide a review of the literature and specific, updated …